Go to content

Relocation European Medicines Agency (EMA)

In 2019 the European Medicines Agency (EMA) relocated from London to Amsterdam. All the information regarding this relocation is still online available.

Decision to relocate

On 20 November 2017, it was decided that the European Medicines Agency would relocate to Amsterdam. The decision to relocate the Agency had to be taken as a consequence of the United Kingdom's decision to leave the European Union. EMA, being a European Agency, therefore had to look for a new European home.

About EMA

EMA plays a key role in the evaluation and authorization of new medicines for the European market. This concerns medicines for both humans and animals. The quality, safety and reliability of these medicines are of paramount importance.

In addition, EMA monitors the safety of medicines already on the market and takes action in the event of risks to public health. EMA also plays a major role in research into and the development of new medicines within the European Union. The Agency was established in 1995 and was based in London until March 2019.

More information about the relocation

In the archive website you will find all information about the relocation. (Please note: Scroll to the bottom of the page and change the language to English.) It concerns the following information:

  • the reason for the relocation;
  • temporary and new EMA building in Amsterdam;
  • support of EMA employees;
  • timeline (an overview of events from the moment the decision was made that EMA would relocate to Amsterdam);
  • news items and news from the media;
  • publications and documents (for more background information).

Documents